https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-01 / Neurotherapeutics 2017 04;14(2):345-357
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-01 / Neurotherapeutics 2017 04;14(2):345-3572017-04-01 00:00:002019-07-01 06:51:35Tumor Vaccines for Malignant Gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-22 / Exp. Cell Res. 2017 05;354(2):112-121
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-22 / Exp. Cell Res. 2017 05;354(2):112-1212017-03-22 00:00:002019-02-15 08:39:30Temperature induces significant changes in both glycolytic reserve and mitochondrial spare respiratory capacity in colorectal cancer cell lines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-22 / J Transl Med 2017 03;15(1):64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-22 / J Transl Med 2017 03;15(1):642017-03-22 00:00:002019-02-15 08:47:53Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-3512017-03-21 00:00:002017-03-21 00:00:00Current status of clinical trials assessing oncolytic virus therapy for urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-13 / Sci Rep 2017 03;7:43961
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-13 / Sci Rep 2017 03;7:439612017-03-13 00:00:002017-03-13 00:00:00Optimizing non-invasive radiofrequency hyperthermia treatment for improving drug delivery in 4T1 mouse breast cancer model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-474
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-4742017-03-05 00:00:002019-02-15 08:47:44Immune and viral therapies for malignant primary brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-02 / Crit. Rev. Oncol. Hematol. 2017 May;113:292-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-02 / Crit. Rev. Oncol. Hematol. 2017 May;113:292-3032017-03-02 00:00:002019-02-15 08:51:58A comprehensive review of immunotherapies in prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-02 / Int J Mol Sci 2017 Mar;18(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-02 / Int J Mol Sci 2017 Mar;18(3)2017-03-02 00:00:002017-03-02 00:00:00Exosomes: From Garbage Bins to Promising Therapeutic Targets
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-01 / Immunotherapy 2017 03;9(4):319-329
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-01 / Immunotherapy 2017 03;9(4):319-3292017-03-01 00:00:002019-02-15 08:48:14Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-27 / Eur. J. Pharmacol. 2017 May;802:85-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-27 / Eur. J. Pharmacol. 2017 May;802:85-922017-02-27 00:00:002019-02-15 09:13:32Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy
